Accéder au contenu
Merck

Chip collection of hepatocellular carcinoma based on O2 heterogeneity from patient tissue.

Nature communications (2024-06-16)
Sewoom Baek, Hyun-Su Ha, Jeong Su Park, Min Jeong Cho, Hye-Seon Kim, Seung Eun Yu, Seyong Chung, Chansik Kim, Jueun Kim, Ji Youn Lee, Yerin Lee, Hyunjae Kim, Yujin Nam, Sungwoo Cho, Kyubae Lee, Ja Kyung Yoon, Jin Sub Choi, Dai Hoon Han, Hak-Joon Sung
RÉSUMÉ

Hepatocellular carcinoma frequently recurs after surgery, necessitating personalized clinical approaches based on tumor avatar models. However, location-dependent oxygen concentrations resulting from the dual hepatic vascular supply drive the inherent heterogeneity of the tumor microenvironment, which presents challenges in developing an avatar model. In this study, tissue samples from 12 patients with hepatocellular carcinoma are cultured directly on a chip and separated based on preference of oxygen concentration. Establishing a dual gradient system with drug perfusion perpendicular to the oxygen gradient enables the simultaneous separation of cells and evaluation of drug responsiveness. The results are further cross-validated by implanting the chips into mice at various oxygen levels using a patient-derived xenograft model. Hepatocellular carcinoma cells exposed to hypoxia exhibit invasive and recurrent characteristics that mirror clinical outcomes. This chip provides valuable insights into treatment prognosis by identifying the dominant hepatocellular carcinoma type in each patient, potentially guiding personalized therapeutic interventions.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Sorafenib, ≥98% (HPLC)
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
RéférenceConditionnementDisponibilitéPrixQuantité
25 g
Date d'expédition estimée le 23 mars 2025
2.865,00 MXP
100 g
Date d'expédition estimée le 23 mars 2025
8.909,00 MXP
500 g
Date d'expédition estimée le 23 mars 2025
19.563,00 MXP